A Placebo‐Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa‐Induced Dyskinesia. Issue 7 (15th March 2016)

• Record Type: Journal Article
• Authors: Trenkwalder, Claudia; Berg, Daniela; Rascol, Olivier; Eggert, Karla; Ceballos‐Baumann, Andres; Corvol, Jean‐Christophe; Storch, Alexander; Zhang, Lin; Azulay, Jean‐Philippe; Broussolle, Emmanuel; Defebvre, Luc; Geny, Christian; Gostkowski, Michal; Stocchi, Fabrizio; Tranchant, Christine; Derkinderen, Pascal; Durif, Franck; Espay, Alberto J.; Feigin, Andrew; Houeto, Jean‐Luc; Schwarz, Johannes; Di Paolo, Thérèse; Feuerbach, Dominik; Hockey, Hans‐Ulrich; Jaeger, Judith; Jakab, Annamaria; Johns, Donald; Linazasoro, Gurutz; Maruff, Paul; Rozenberg, Izabela; Sovago, Judit; Weiss, Markus; Gomez‐Mancilla, Baltazar;
• Is Part Of: Movement disorders. Volume 31:Issue 7(2016)
• Page Start: 1049
• Page End: 1054
• Publication Date: 2016-03-15
• Subjects: Parkinson's disease -- levodopa (l‐dopa) -- nicotinic acetylcholine receptor agonist (nAChR) α7 -- AQW051 -- dyskinesias; Movement disorders -- Periodicals; 610
• DOI: 10.1002/mds.26569
• Languages: English
• ISSNs: 0885-3185

Abstract

ABSTRACT: Background: This phase 2 randomized, double‐blind, placebo‐controlled study evaluated the efficacy and safety of the nicotinic acetylcholine receptor α7 agonist AQW051 in patients with Parkinson's disease and levodopa‐induced dyskinesia. Methods: Patients with idiopathic Parkinson's disease and moderate to severe levodopa‐induced dyskinesia were randomized to AQW051 10 mg (n = 24), AQW051 50 mg (n = 24), or placebo (n = 23) once daily for 28 days. Coprimary end points were change in Modified Abnormal Involuntary Movement Scale and Unified Parkinson's Disease Rating Scale part III scores. Secondary outcomes included pharmacokinetics. Results: In total, 67 patients completed the study. AQW051‐treated patients experienced no significant improvements in Modified Abnormal Involuntary Movement Scale or Unified Parkinson's Disease Rating Scale part III scores by day 28. AQW051 was well tolerated; the most common adverse events were dyskinesia, fatigue, nausea, and falls. Conclusions: AQW051 did not significantly reduce dyskinesia or parkinsonian severity. © 2016 International Parkinson and Movement Disorder Society